India, March 12 -- Alkem Laboratories announced the launch of generic empagliflozin and its combinations in India under the brand name 'Empanorm' at prices that are approximately 80% lower than the innovator products.Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). Alkem's generic empagliflozin and its combinations are bioequivalent to innovator products.With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infograp...